Market Closed -
Nasdaq
04:30:00 2024-04-26 pm EDT
5-day change
1st Jan Change
1.51
USD
-5.62%
-15.17%
-43.45%
Presentation Operator MessageOperator (Operator)Good afternoon, and welcome to the Cyclacel Ph...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer
Apr. 01
CI
Transcript : Cyclacel Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 19, 2024
Mar. 19
Earnings Flash (CYCC) CYCLACEL Posts Q4 Revenue $31,000
Mar. 19
MT
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Mar. 19
CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 19
CI
Cyclacel Pharmaceuticals, Inc. Announces Board Changes
Jan. 30
CI
Cyclacel Pharmaceuticals, Inc. Announces Executive Changes
Jan. 30
CI
Top Premarket Gainers
Jan. 08
MT
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $0.026374 million in funding
Dec. 21
CI
North American Morning Briefing : S&P 500 Futures -2-
Dec. 20
DJ
Brookline Capital Downgrades Cyclacel Pharmaceuticals to Hold From Buy
Dec. 19
MT
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
Dec. 18
CI
Transcript : Cyclacel Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 13, 2023
Nov. 13
Earnings Flash (CYCC) CYCLACEL Reports Q3 Revenue $16,000
Nov. 13
MT
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023
Nov. 13
CI
Cyclacel Pharmaceuticals Files $100 Million Mixed Shelf
23-09-05
MT
Transcript : Cyclacel Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 09, 2023
23-08-09
Earnings Flash (CYCC) CYCLACEL Posts Q2 Revenue $373,000
23-08-09
MT
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023
23-08-09
CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-11
CI
Transcript : Cyclacel Pharmaceuticals, Inc., Q1 2023 Earnings Call, May 11, 2023
23-05-11
Oppenheimer Adjusts Cyclacel Pharmaceuticals Price Target to $8 From $10, Maintains Outperform Rating
23-03-07
MT
Transcript : Cyclacel Pharmaceuticals, Inc., Q4 2022 Earnings Call, Mar 06, 2023
23-03-06
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-06
CI
Cyclacel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
23-03-06
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
More about the company
Last Close Price
1.51
USD
Average target price
163
USD
Spread / Average Target
+10,694.70%
Consensus
1st Jan change
Capi.
-43.45% 1.99M -2.31% 103B +0.56% 95.28B +1.69% 22.15B -17.37% 21.02B -9.30% 18.15B -41.01% 16.74B -14.85% 16.05B +3.21% 13.68B +33.54% 12.17B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1